Bay Labs has collaborated with Edwards Lifesciences to use artificial intelligence (AI) software for detection of heart disease.
The companies will develop novel artificial intelligence (AI) powered algorithms in Bay Labs’ EchoMD software set. Additionally, the algorithms of EchoMD will be combined with Edwards Lifesciences’ CardioCare quality care navigation platform.
The companies will also provide support to institutional clinical trials.
Bay Labs is a medical technology, while Edwards Lifesciences is a provider of medical devices. Both companies are based in the US.
LumiThera has partnered with Miloftalmica for the exclusive distribution of the Valeda Light Delivery System in Italy.
LumiThera’s Valeda is indicated for the treatment of dry age-related macular degeneration (AMD).
The partnership will allow LumiThera to enhance its marketing efforts in Europe.
LumiThera is a medical device company based in the US. Miloftalmica is a diagnostic ophthalmic technology distributor from Italy.
Medovate has secured an exclusive licence for the design, development, manufacture and commercialisation of two complementary local anaesthesia devices named Regional Anaesthesia Device (RADS) and Safer Injection for Regional Anaesthesia (SAFIRA).
RADS was developed in collaboration with the Leeds Teaching Hospitals NHS Trust, while SAFIRA was developed with Queen Elizabeth Hospital.
Medovate is a medical technology company based in the UK.
US ARKRAY has signed an agreement with Medline Industries to distribute its range of medical diagnostic devices to physician office laboratories.
The devices include the ADAMS A1c HA-8180V fully automated HPLC HbA1c analyser, AUTION MAX AX-4030 fully automated urine chemistry analyser, and AUTION ELEVEN AE-4022 semi-automated urine chemistry analyser.
US ARKRAY is a medical devices company, while Medline Industries is a medical product supplier. Both companies are based in the US.
Roche has partnered with Merck for the development of pan-cancer companion diagnostic device to identify patients with advanced solid tumours who are eligible to receive PD-1 inhibitor therapy.
The device will be developed for use on Roche’s BenchMark ULTRA instrument.
Roche is based in Switzerland, while Merck is headquartered in the US.